Orient EuroPharma Co., Ltd. (TPEX:4120)
Taiwan · Delayed Price · Currency is TWD 46.10
-1.60 (-3.35%)
Mar 26, 2026, 1:30 PM CST
Orient EuroPharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,595 | 4,391 | 4,592 | 4,730 | 4,767 | |
Revenue Growth (YoY) | 4.64% | -4.37% | -2.93% | -0.77% | -11.45% |
Cost of Revenue | 2,358 | 2,325 | 2,445 | 2,698 | 2,616 |
Gross Profit | 2,237 | 2,066 | 2,147 | 2,032 | 2,151 |
Selling, General & Admin | 1,978 | 1,811 | 1,868 | 1,922 | 1,918 |
Research & Development | 558.41 | 242.22 | 206.6 | 259.84 | 331.09 |
Operating Expenses | 2,548 | 2,073 | 2,077 | 2,182 | 2,246 |
Operating Income | -310.54 | -6.72 | 70.61 | -149.54 | -95.68 |
Interest Expense | -74.06 | -107.23 | -106.1 | -69.53 | -38.04 |
Interest & Investment Income | 34.38 | 48.87 | 50.86 | 20.96 | 11.85 |
Earnings From Equity Investments | -61.01 | -27.29 | -18.27 | -30.14 | -19.14 |
Currency Exchange Gain (Loss) | - | -111.86 | -25.59 | -177.51 | 11.6 |
Other Non Operating Income (Expenses) | 138.2 | 71.11 | 50.08 | 40.54 | 41.69 |
EBT Excluding Unusual Items | -273.03 | -133.1 | 21.6 | -365.23 | -87.71 |
Gain (Loss) on Sale of Investments | - | 6.15 | - | - | - |
Gain (Loss) on Sale of Assets | - | -4.83 | 234.5 | 72.35 | 182.38 |
Asset Writedown | - | - | - | -35.3 | -10 |
Other Unusual Items | - | 1.8 | 0.16 | 0.05 | 0.1 |
Pretax Income | -273.03 | -129.99 | 256.25 | -328.14 | 84.77 |
Income Tax Expense | 207.16 | 101.21 | 86.97 | -32.77 | 10.47 |
Earnings From Continuing Operations | -480.19 | -231.2 | 169.29 | -295.37 | 74.3 |
Minority Interest in Earnings | -87.2 | -52.74 | -25.34 | -15.44 | 45.88 |
Net Income | -567.39 | -283.93 | 143.94 | -310.8 | 120.17 |
Net Income to Common | -567.39 | -283.93 | 143.94 | -310.8 | 120.17 |
Net Income Growth | - | - | - | - | -39.70% |
Shares Outstanding (Basic) | 87 | 87 | 87 | 87 | 87 |
Shares Outstanding (Diluted) | 87 | 87 | 87 | 87 | 87 |
Shares Change (YoY) | 0.01% | -0.23% | 0.23% | -0.24% | -0.21% |
EPS (Basic) | -6.54 | -3.27 | 1.66 | -3.58 | 1.39 |
EPS (Diluted) | -6.54 | -3.27 | 1.66 | -3.58 | 1.38 |
EPS Growth | - | - | - | - | -39.74% |
Free Cash Flow | -465.88 | -220.16 | -34.73 | -857.91 | -1,485 |
Free Cash Flow Per Share | -5.37 | -2.54 | -0.40 | -9.89 | -17.08 |
Dividend Per Share | - | 1.000 | 1.000 | - | 0.850 |
Dividend Growth | - | - | - | - | -43.33% |
Gross Margin | 48.69% | 47.05% | 46.76% | 42.96% | 45.12% |
Operating Margin | -6.76% | -0.15% | 1.54% | -3.16% | -2.01% |
Profit Margin | -12.35% | -6.47% | 3.14% | -6.57% | 2.52% |
Free Cash Flow Margin | -10.14% | -5.01% | -0.76% | -18.14% | -31.16% |
EBITDA | -112.75 | 153.46 | 235.75 | 7.04 | 60.33 |
EBITDA Margin | -2.45% | 3.50% | 5.13% | 0.15% | 1.27% |
D&A For EBITDA | 197.79 | 160.18 | 165.14 | 156.57 | 156.01 |
EBIT | -310.54 | -6.72 | 70.61 | -149.54 | -95.68 |
EBIT Margin | -6.76% | -0.15% | 1.54% | -3.16% | -2.01% |
Effective Tax Rate | - | - | 33.94% | - | 12.35% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.